This suggests that ambroxol is inducing a general increase in lysosomal mass, with improvement of glucosylceramidase activity in Gaucher disease, Parkinson’s disease with GBA mutations and non-manifesting carriers resulting in a fall in cathepsin D and beta-hexosaminidase activity. Here, CTSD is linked to Parkinson disease.